N-Methyl-d-aspartate Antagonists and WIN 55212-2 [4,5-Dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6 H-pyrrolo[3,2,1-i,j]quinolin-6-one], a Cannabinoid Agonist, Interact to Produce Synergistic Hypothermia
- 1 January 2002
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 303 (1) , 395-402
- https://doi.org/10.1124/jpet.102.037473
Abstract
CB1 cannabinoid receptors mediate profound hypothermia when cannabinoid agonists are administered to rats. Glutamate, the principal excitatory neurotransmitter in the central nervous system (CNS), is thought to tonically increase body temperature by activatingN-methyl-d-aspartate (NMDA) receptors. Because NMDA antagonists block cannabinoid-induced antinociception and catalepsy, intimate glutamatergic-cannabinoid interactions may exist in the CNS. The present study investigated the effect of two NMDA antagonists on the hypothermic response to WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1-i,j]quinolin-6-one], a selective cannabinoid agonist, in rats. WIN 55212-2 (1–10 mg/kg i.m.) produced dose-dependent hypothermia that peaked 60 to 180 min postinjection. Dextromethorphan (5–75 mg/kg i.m.), a noncompetitive NMDA antagonist, or LY 235959 [(−)-6-[phosphonomethyl-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-2-carboxylate]](1–4 mg/kg i.m.), a competitive and highly selective NMDA antagonist, evoked hypothermia in a dose-sensitive manner, suggesting that endogenous glutamate exerts a hyperthermic tone on body temperature. A dose of dextromethorphan (10 mg/kg) that did not affect body temperature by itself potentiated the hypothermic response to WIN 55212-2 (1, 2.5, or 5 mg/kg). The enhancement was strongly synergistic, indicated by a 2.7-fold increase in the relative potency of WIN 55212-2. Similarly, a dose of LY 235959 (1 mg/kg) that did not affect body temperature augmented the hypothermia associated with a single dose of WIN 55212-2 (2.5 mg/kg), thus confirming that NMDA receptors mediated the synergy. We have demonstrated previously that CB1 receptors mediate WIN 55212-2-evoked hypothermia in rats. The present data are the first evidence that NMDA antagonists exert a potentiating effect on cannabinoid-induced hypothermia. Taken together, these data suggest that interactions between NMDA and CB1 receptors produce synergistic hypothermia.Keywords
This publication has 36 references indexed in Scilit:
- Hypokalemia and Alkalosis in Adipsic Hypernatremia Are Not Associated with HyperaldosteronismHormone Research in Paediatrics, 2004
- Involvement of somatodendritic 5-HT1A receptors in Δ9-tetrahydrocannabinol-induced hypothermia in the ratPharmacology Biochemistry and Behavior, 2001
- Differential effects of LY235959, a competitive antagonist of the NMDA receptor on κ-opioid receptor agonist induced responses in mice and ratsBrain Research, 1997
- HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5Nature, 1996
- Pharmacology of Cannabinoid ReceptorsAnnual Review of Pharmacology and Toxicology, 1995
- Competitive NMDA antagonists enhance the catalepsy induced by Δ9-tetrahydrocannabinol in miceNeuroscience Letters, 1994
- Dextromethorphan and neuromodulation: old drug coughs up new activitiesTrends in Pharmacological Sciences, 1989
- Comparison of the effects of the acute administration of dexoxadrol, levoxadrol, MK-801 and phencyclidine on body temperature in the ratNeuropharmacology, 1989
- Dextromethorphan and dextrorphan as calcium channel antagonistsBrain Research, 1988
- Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compoundsLife Sciences, 1984